Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
The latest in tricuspid valve care | Bivalirudin vs. heparin | Cardiologists develop how-to guide for home-based care
Wednesday, September 27, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

What new tricuspid valve data tell us about the future of patient care

What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out. 

READ MORE >
Video of Prof. Dr. Ralph Stephan von Bardeleben explaining the latest details from key tricuspid valve trials.
Share on Twitter Share on Facebook Share on Linkedin

What new tricuspid valve data tell us about the future of patient care

Share on Twitter Share on Facebook Share on Linkedin
Video of Prof. Dr. Ralph Stephan von Bardeleben explaining the latest details from key tricuspid valve trials.
What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out. 
READ MORE >

Bivalirudin linked to key benefit over heparin for NSTEMI patients undergoing PCI

The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin. 

READ MORE >
Tablet projecting metaphorical medical hologram
Share on Twitter Share on Facebook Share on Linkedin

Bivalirudin linked to key benefit over heparin for NSTEMI patients undergoing PCI

Share on Twitter Share on Facebook Share on Linkedin
Tablet projecting metaphorical medical hologram
The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin. 
READ MORE >

Cardiologists develop how-to guide for providing high-quality care from the comfort of home

“Many within the healthcare industry believe that cardiovascular care will be increasingly delivered in non-traditional ambulatory settings,” according to one author. “The cardiovascular care community must consider and prepare for this eventuality."

READ MORE >
older patient with a doctor at their house
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists develop how-to guide for providing high-quality care from the comfort of home

Share on Twitter Share on Facebook Share on Linkedin
older patient with a doctor at their house
“Many within the healthcare industry believe that cardiovascular care will be increasingly delivered in non-traditional ambulatory settings,” according to one author. “The cardiovascular care community must consider and prepare for this eventuality."
READ MORE >

Featured Articles

Surgeons make history again, transplant pig heart into human patient for second time ever

That same team that transplanted a pig heart into a human patient for the very first time in 2022 has now done it again. The patient is currently recovering from the procedure, which occurred on Sept. 20. 

READ MORE >
Surgeons with University of Maryland Medical Center transplant a pig heart into a human patient for only the second time ever on Sept. 20 2023. Bartley P. Griffith, MD, a professor of surgery and clinical director of the cardiac xenotransplantation program at the University of Maryland School of Medicine (UMSOM), and Muhammad M. Mohiuddin, MD, scientific director of the cardiac xenotransplantation program at UMSOM, performed the historic procedure. #pigheart
Share on Twitter Share on Facebook Share on Linkedin

Surgeons make history again, transplant pig heart into human patient for second time ever

Share on Twitter Share on Facebook Share on Linkedin
Surgeons with University of Maryland Medical Center transplant a pig heart into a human patient for only the second time ever on Sept. 20 2023. Bartley P. Griffith, MD, a professor of surgery and clinical director of the cardiac xenotransplantation program at the University of Maryland School of Medicine (UMSOM), and Muhammad M. Mohiuddin, MD, scientific director of the cardiac xenotransplantation program at UMSOM, performed the historic procedure. #pigheart
That same team that transplanted a pig heart into a human patient for the very first time in 2022 has now done it again. The patient is currently recovering from the procedure, which occurred on Sept. 20. 
READ MORE >

Novo Nordisk spends $60M on advanced AI in search of new cardiovascular medications

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 

READ MORE >
artificial intelligence robot evaluates healthcare data. Novo Nordisk announced a new collaboration with Valo Health, a healthcare technology company focused on using artificial intelligence (AI) technology to identify new drug treatments for cardiovascular disease (CVD).
Share on Twitter Share on Facebook Share on Linkedin

Novo Nordisk spends $60M on advanced AI in search of new cardiovascular medications

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence robot evaluates healthcare data. Novo Nordisk announced a new collaboration with Valo Health, a healthcare technology company focused on using artificial intelligence (AI) technology to identify new drug treatments for cardiovascular disease (CVD).
Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 
READ MORE >

Warfarin after TAVR is safe, but fails to boost outcomes

Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own. 

READ MORE >
Pills
Share on Twitter Share on Facebook Share on Linkedin

Warfarin after TAVR is safe, but fails to boost outcomes

Share on Twitter Share on Facebook Share on Linkedin
Pills
Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own. 
READ MORE >

In Case You Missed It

‘Horrible and atrocious’: Denver cardiologist accused of date rape by multiple women is headed to trial

The 35-year-old cardiologist faces a total of 51 felony charges. He is scheduled to be arraigned on Oct. 6.

READ MORE >
Judge bangs gavel
Share on Twitter Share on Facebook Share on Linkedin

‘Horrible and atrocious’: Denver cardiologist accused of date rape by multiple women is headed to trial

Share on Twitter Share on Facebook Share on Linkedin
Judge bangs gavel
The 35-year-old cardiologist faces a total of 51 felony charges. He is scheduled to be arraigned on Oct. 6.
READ MORE >

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Share on Twitter Share on Facebook Share on Linkedin
Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 
READ MORE >

In Other News

AI-powered stroke triage software meaningfully reduces treatment times, randomized trial finds

The investigation also used secure messaging, allowing clinicians to receive real-time alerts via their smartphones to notify them of a possible LVO minutes after the completion of a CT. 

READ MORE >
Stroke - head with text
Share on Twitter Share on Facebook Share on Linkedin

AI-powered stroke triage software meaningfully reduces treatment times, randomized trial finds

Share on Twitter Share on Facebook Share on Linkedin
Stroke - head with text
The investigation also used secure messaging, allowing clinicians to receive real-time alerts via their smartphones to notify them of a possible LVO minutes after the completion of a CT. 
READ MORE >

5 reasons healthcare needs ‘ownership transparency’ now

Do you know who owns your personal favorite doctor’s practice? Could it be a healthcare conglomerate? An insurance company? A private equity firm? Amazon?

READ MORE >
healthcare ownership pricing billing transparency
Share on Twitter Share on Facebook Share on Linkedin

5 reasons healthcare needs ‘ownership transparency’ now

Share on Twitter Share on Facebook Share on Linkedin
healthcare ownership pricing billing transparency
Do you know who owns your personal favorite doctor’s practice? Could it be a healthcare conglomerate? An insurance company? A private equity firm? Amazon?
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup